DrugPatentWatch Database Preview

Pfizer Company Profile

PFIZER has one hundred and fifty-five approved drugs.

There are forty-nine US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand two hundred and ninety-three patent family members on PFIZER drugs in seventy-six countries and one hundred and ninety-one supplementary protection certificates in seventeen countries.

International Patents:	1293
US Patents:	49
Tradenames:	122
Ingredients:	108
NDAs:	155
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-003	Sep 27, 2018		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Pfizer Inc	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No		➤ Sign Up				➤ Sign Up
Pfizer	DARICON	oxyphencyclimine hydrochloride	TABLET;ORAL	011612-001	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999	AB	RX	Yes	No	RE44459	➤ Sign Up				➤ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TROVAN PRESERVATIVE FREE	alatrofloxacin mesylate	INJECTABLE;INJECTION	020760-002	Dec 18, 1997	5,164,402	➤ Sign Up
Pfizer	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996	4,375,547	➤ Sign Up
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-003	Apr 6, 1982	3,591,584	➤ Sign Up
Pfizer	MINIZIDE	polythiazide; prazosin hydrochloride	CAPSULE;ORAL	017986-003	Approved Prior to Jan 1, 1982	3,511,836	➤ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Capsules	200 mg/38 mg	➤ Subscribe	2016-02-16
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2009-04-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25
➤ Subscribe	Capsules	200 mg/30 mg	➤ Subscribe	2004-12-27
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Tablets	5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg	➤ Subscribe	2006-12-29
➤ Subscribe	Tablets	2.5 mg/40 mg	➤ Subscribe	2009-09-17
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26

Patent Number	Expiration Date
➤ Sign Up	➤ Sign Up

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2107069	C201300035	Spain	➤ Sign Up	PRODUCT NAME: INSULINA DEGLUDEC; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF FIRST AUTHORISATION IN EEA: 20130121
1077912	91365	Luxembourg	➤ Sign Up	91365, EXPIRES: 20220420
2209800	1490067-4	Sweden	➤ Sign Up	PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
0473687	3/1999	Austria	➤ Sign Up	PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.